Skip to main content
. 2008 Nov 4;99(11):1775–1785. doi: 10.1038/sj.bjc.6604769

Figure 3.

Figure 3

OS (A1 and A2) and DFS (B1 and B2) for patients treated with (red line) or without (blue line) paclitaxel, according to HER2 mRNA expression. A1 and B1 (HER2 <median): 55 (41%) E-T-CMF and 79 (59%) E-CMF-treated patients. A2 and B2 (HER2⩾median): 62 (46%) E-T-CMF and 72 (54%) E-CMF-treated patients.